Recent Headlines
Within Biotechnology
Creative BioMart Enhances Host Cell Protein Mitigation Service to Strengthen Biotherapeutic Quality
Creative BioMart, a leading biotechnology company specializing in protein and biopharmaceutical solutions, has announced an enhancement to its host cell protein service. The upgraded offering introduces a more integrated and data-driven approach to identifying, quantifying, and reducing host cell... - December 11, 2025 - Creative BioMart
DDi Selected by a Large $2 Billion Medical Device Company to Streamline Regulatory Strategy, Intelligence and Assessments
DDi has been selected by a UK-based US $2B medical-device company to streamline its global regulatory strategy, intelligence operations, and regulatory assessments. The partnership strengthens compliance, accelerates market readiness, and leverages DDi’s advanced Visu regulatory-process platform. - November 24, 2025 - DDi LLC
DelivHer Launches Anu™ by DelivHer: The First Disposable, Fluid-Retentive Menstrual Disc Designed Specifically for Heavy, Clot-Rich Flow
Anu™ by DelivHer stands apart from other menstrual discs and cups with its fluid-retentive Leak-Lock™ technology, locking in both fluid and clots for leak-free, extended wear and mess-free removal - finally providing real protection for women with heavier-than-normal cycles. - November 17, 2025 - Anu by DelivHer
Parvus Therapeutics Reports Positive Phase 1 Results for Lead Autoimmune Treg Therapy, PVT201
PVT201 demonstrated favorable safety, predictable pharmacokinetics, and on-target pharmacodynamic activity in first-in-human study. - November 12, 2025 - Parvus Therapeutics U.S., Inc.
Alera Bio Announces Appointment of Board of Directors
Alera Bio, a Chicago-based biotech developing therapies for rare neuroendocrine and neurological disorders, announced its inaugural Board of Directors. The board includes leaders in biopharma, clinical practice, and finance, such as Stephen Hill, Mark Prygocki, Renny Griffith, and Cassius Coleman. Their combined expertise will guide Alera Bio as it advances AB-101 for MCT-8 deficiency, an FDA-designated Rare Pediatric Disease therapy. - November 11, 2025 - Alera Bio
McObject Releases eXtremeDB/rt 2.0: Persistent Hard Real-Time Database System with Breakthrough Deadline and Flash Memory Control
McObject has released eXtremeDB/rt 2.0, the next evolution of its hard real-time database system. Now supporting persistent storage with deterministic flash management and advanced deadline scheduling, version 2.0 ensures predictable performance even under extreme workload and timing constraints. Ideal for aerospace, industrial, and safety-critical environments where timing precision truly matters. - November 04, 2025 - McObject
MVT Reports Breakthrough Preclinical Results for MVT‑101 in DVT Model
Microvascular Therapeutics, Inc. (MVT) today announced the publication of compelling preclinical data demonstrating that its proprietary phase‑shift microbubble platform, MVT‑101 (Solv), significantly enhances sonothrombolysis in a clinically relevant porcine model of deep vein thrombosis (DVT). The study appears in the peer‑reviewed journal Nanotheranostics (Vol. 9, Issue 3, 2025). - November 04, 2025 - Microvascular Therapeutics, Inc.
Ales for ALS Reaches 300+ Breweries in 2025 — Limited Spots Still Open to Join This Year
Ales for ALS™ announced today that more than 300 breweries across the United States and around the world have joined the 2025 program—poised to make this year one of the largest in the initiative’s 12-year history. Limited hop allocations remain available, and interested breweries are encouraged to enroll soon to secure one of the final shipments for the year. - October 31, 2025 - ALS Therapy Development Institute
New Study Shows Self-Guided Online Exercise Program Significantly Improves Strength and Reduces Fall Risk in Midlife and Older Women
A new study to be presented at The Menopause Society (TMS) 2025 Annual Meeting by Osteoboost Health shows that a self-guided, online exercise program led to rapid and clinically meaningful improvements in leg strength and endurance — key factors in reducing fall risk — in women ages 40... - October 21, 2025 - Osteoboost Health
Cancer Prevention Nanomedicine Platform Advances Toward Preclinical Development Phase
Elixira, a Swedish nanomedicine innovation designed to function as an artificial immune system for lifelong cancer prevention, is preparing for the preclinical development phase — marking a key milestone toward the world’s first preventive nanomedicine platform. The company has now... - October 19, 2025 - Elixira
New Report Uncovers What Sponsors Really Think About Preclinical Services and CROs
Life Science Strategy Group’s Preclinical Services Landscape and CRO Benchmarking Assessment Delivers Data-Driven Insights on Budgets, Outsourcing, Vendor Preferences, and Industry Shifts - October 16, 2025 - Life Science Strategy Group, LLC
Cellionyx Exits Stealth Mode with Cytomotion, an FDA-Registered Class I Electroceutical Device Set to Redefine Human Healing and Performance
Cellionyx today emerged from stealth to launch Cytomotion, a first-in-class, FDA-Registered Class I medical device. Shifting the paradigm to true cellular regeneration, Cytomotion utilizes precision-directed electrical fields to activate the body’s innate repair mechanisms. Validated through its licensee Equstech in the elite high performance equestrian sports market, the technology accelerates recovery from injury and proactively optimizes human performance. Commercial launch November 12, 2025. - October 13, 2025 - Cellionyx
Abel Womack Launches Newly Redesigned Website
Enhancing Customer Experience Across Forklift, Automation, and Intralogistics Solutions - October 01, 2025 - Abel Womack Inc
Aquaterra Biotech Launches Integrated DNA-to-GMP CDMO Platform in Québec
Aquaterra Biotech Launches Integrated Microbial CDMO Platform from DNA Design to GMP Release Aquaterra Biotech announced an integrated contract development and manufacturing (CDMO) platform that advances microbial and recombinant programs from DNA design to GMP release and logistics. Headquartered... - September 30, 2025 - Aquaterra Biotech
The FOXG1 Research Foundation Announces FDA Award of Orphan Drug Designation for FRF-001 Gene Therapy, Following Rare Pediatric Disease Designation
The FOXG1 Research Foundation announced the FDA has granted Orphan Drug and Rare Pediatric Disease designations to FRF-001, its gene therapy for FOXG1 syndrome. FRF-001 marks a historic first: a parent-led foundation sponsoring its own international, multi-site clinical trial. - September 29, 2025 - FOXG1 Research Foundation
Alera Bio Announces Appointment of Executive Leadership Team
Alera Bio announced its executive team: Philip Vorhies (CEO), Peter Thomson (CFO), Eric Floyd, PhD (CRO), and Caitlin Murray (GC), supported by expert consultants. Founder Frank Jaeger noted their strength in biotech, finance, regulatory, and legal, positioning Alera to advance AB-101 for MCT-8 deficiency, a rare neurological disorder with FDA Rare Pediatric Disease designation. - September 26, 2025 - Alera Bio
French Biotech 4Dcell Selected to Showcase Next-Gen Cardiac Drug Testing Platform at EIC Corporate Day
French Startup 4Dcell Wins Spot to Show Next-Gen Cardiac Drug Testing Platform at EIC - September 24, 2025 - 4Dcell
YOLO Immune Awarded National Science Foundation SBIR Grant to Advance Novel Immunotherapy for the Treatment of Autoimmune Diseases
YOLO Immune, Inc., a venture-backed biotech company developing precision immunotherapies for the treatment of serious human diseases, today announced it has been awarded a Phase I Small Business Innovation Research (SBIR) grant from the National Science Foundation (NSF). The NSF SBIR program is... - September 19, 2025 - YOLO Immune Inc
Alera Bio Launches Lead Rare Disease Program with Exclusive Rights to MCT-8 Deficiency Therapy
Alera Bio secures exclusive license to advance AB-101, a first-in-class program for MCT-8 deficiency, with FDA Rare Pediatric Disease designation already in place. - September 18, 2025 - Alera Bio
National Brain Tumor Society Appoints Renowned Pediatric Oncologist as Chief Scientific Officer
National Brain Tumor Society names leading pediatric cancer expert, Dr. Susan Blaney, as new Chief Scientific Officer. - September 08, 2025 - National Brain Tumor Society
DDi added more AI Agents to enhance Regulatory Strategy, Planning, and Project Actions
DDi introduces AI Agents for Strategy, Planning, and Actions, including Regulatory Insights, Regulatory Impact, and Planning Agents. These tools provide compliance visibility, assess regulatory impacts, and optimize planning, enabling organizations to act with confidence and agility. - August 22, 2025 - DDi LLC
CABRI Fellowship Program Opens for Undergraduate Research Applicants
The Cayman Biomedical Research Institute (CABRI) has announced that applications are now open for their undergraduate research fellowships. Applications may be submitted on the CABRI website from August 11, 2025 through September 29, 2025. - August 15, 2025 - Cayman Chemical Company
YOLO Immune Inc. Emerges from Stealth Mode
YOLO Immune Inc. has emerged from stealth mode to unveil its human-centric drug discovery process and to announce the promotion of its founding research team. YOLO Immune is a venture-backed biotech company developing precision immunotherapies for the treatment of serious human diseases. The... - July 31, 2025 - YOLO Immune Inc
Phenotap, Inc. Receives Progr. Related Investment from Helmsley Charitable Trust to Advance Breakthrough Ketone Sensor Technology for People Living with Type 1 Diabetes
Phenotap, Inc. announced a $3 million investment to support the continued development and optimization of KetoTap™ Core, a novel enzymatic technology, to make it active and stable enough to be used as part of a continuous ketone sensor that can help prevent the occurrence of diabetic ketoacidosis (DKA) for people living with type 1 diabetes (T1D). - July 14, 2025 - Phenotap, Inc.
Alera Bio Launches to Advance Breakthrough Therapies for Rare Neurological Disorders
Chicago-based Alera Bio has launched with a mission to develop treatments for ultra-rare and neglected neurological disorders, especially in children. Combining scientific innovation with patient urgency, the company will pursue both novel and repurposed therapies via orphan drug and 505(b)(2) pathways. With a lean, capital-efficient model, Alera Bio aims to rapidly advance therapies that address critical gaps in care. - July 03, 2025 - Alera Bio
DDi’s Visu Regulatory Platform Now with AI-Powered Project Management & Impact Assessment
DDi enhances its Visu platform with AI-driven project management tools, offering increased efficiency, real-time insights, and risk mitigation for pharma, biotech, and medical device industries. - June 29, 2025 - DDi LLC
Locus FS Announces Executive Appointments and Strategic Market Focus
Biotechnology company strengthens market position with new board and sharper commercial focus in oil & gas, mining, agriculture and industrial/CPG. - June 26, 2025 - Locus Fermentation Solutions
ALS TDI Announces New Agreement with Axol Bioscience to Expand Access to ALS Patient iPSC-Derived Cells for Global Research
The ALS Therapy Development Institute (ALS TDI) is proud to announce that a collection of cells derived from ALS patient-derived induced pluripotent stem cell (iPSC) lines will now be made widely available to researchers around the world. - June 24, 2025 - ALS Therapy Development Institute
MtoZ Biolabs Launches Precision Chemical Proteomics Analysis Service
Chemical proteomics analysis service combines synthetic chemistry, cell biology, and mass spectrometry to profile small molecule–protein interactions for target identification, mechanism studies, and off-target evaluation. MtoZ Biolabs provides a one-stop chemical proteomics analysis service featuring Orbitrap MS, advanced probe design, and AI-driven analysis, supporting hit validation, candidate de-risking, and mechanistic research with high resolution and biological relevance. - June 20, 2025 - MtoZ Biolabs
New RNA Category: Self-Amplifiying RNAs (saRNAs) Are Now Available for a Longer Expression Period
Self-amplifying RNAs (saRNAs) also called “Replicons” are the next generation of RNA vaccines. Their advantage over conventional mRNA vaccine platforms relies on the viral replication machinery, which amplifies the mRNA of the encoded gene of interest within target cells. - June 20, 2025 - OZ Biosciences
Hundreds of Cyclists to Ride Through Durham, NH, June 21–22, to Raise Funds for ALS Research
On June 21, hundreds of cyclists will ride through Durham, NH, as part of the Tri-State Trek—New England’s premier ALS fundraising bike ride. This inspiring event raises critical funds for the ALS Therapy Development Institute, a nonprofit biotech leading the charge in developing effective treatments for ALS. The Trek brings together local families, riders, and volunteers in a powerful show of support for those living with this devastating disease. - June 16, 2025 - ALS Therapy Development Institute
3rd Annual ALS 100 Hole Challenge Set for June 17, 2025, in Hartford, CT
On Tuesday, June 17, 2025, twenty-four passionate golfers will take on a marathon challenge—playing 100 holes of golf in a single day—to raise critical funds and awareness in the fight against ALS. The third annual ALS 100 Hole Challenge will take place at Keney Park Golf Course in... - June 09, 2025 - ALS Therapy Development Institute
H3Tech Welcomes Ruiban Coutinho as AI Healthtech Consultant
H3Tech, a healthcare technology and consulting firm, has appointed Ruiban Coutinho as AI Healthtech Consultant. With 14 years of experience in data analytics and business intelligence, Coutinho will leverage his expertise in AI, SAP BW/HANA, and Power BI to enhance H3Tech’s AI-driven healthcare solutions. - June 06, 2025 - H3Tech
No Collars, No Limits: HALO Chip Brings Real-Time GPS Tracking Under the Skin
HALO Technologies, Inc. has developed an implantable GPS microchip for pets and wildlife. Now in pre-launch, The HALO Chip offers discreet, real-time tracking without external devices. - May 28, 2025 - Halo Technologies Inc
Phytobiosomes by Costas Picadas
Henri Dunant Hospital proudly presents Costas Picadas: Phytobiosomes, a unique exhibition of prints and digital installations that opened on Monday, May 19, 2025, and runs through Tuesday, September 30, 2025. The internationally recognized New York-based art historian Dr. Thalia Vrachopoulos curated the exhibition. - May 22, 2025 - Costas Picadas
The New Gods of Medicine Summit Debuts in Cannes This June
Longevity Docs Presents: The New Gods of Medicine Summit Debuts in Cannes This June. - May 21, 2025 - Longevity Docs
Microvascular Therapeutics: Positive Clinical Trial Results with Lead Candidate, CardiSon (MVT-100)
Microvascular Therapeutics, Inc. (MVT), a biotechnology company, announced that it has completed data analysis of its Phase II trial of its new ultrasound contrast agent, MVT-100, CardiSon, in echocardiography. In this study, 16 subjects received either the predicate agent Perflutren, or CardiSon,... - May 15, 2025 - Microvascular Therapeutics, Inc.
ReLiftMD Reports Over 2,000 Successful Patient Treatments -- Re•Lift Me™ One-Hour Facial Rejuvenation Procedures Deliver Decade-Younger Looks Under Local Anesthesia
ReLiftMD LLC is changing the aesthetic landscape with its novel Re•Lift Me™ minimally invasive, long-lasting facial rejuvenation procedures. These procedures enable individuals to achieve a naturally youthful appearance, looking up to ten years younger, through a simple, one-hour procedure performed under local anesthesia. - May 07, 2025 - ReLiftMD, LLC
Industry-First Platform Combines AI-Powered Simulation and Lab Testing for Faster Biodegradation Assessment
Aropha's Biodegradation Studio is transforming how product developers approach biodegradability testing. The new platform combines rapid, AI-powered simulation with accredited laboratory services. Users can manage and accelerate every stage of biodegradability testing — from virtual screening to lab validation —through one, centralized hub. The studio helps R&D teams cut costs, screen more chemicals, speed up development and bring biodegradable materials to market faster. - May 06, 2025 - Aropha
Vetirus Pharmaceuticals Acquires Enso Discoveries to Expand Regenerative Medicine Portfolio
Vetirus Pharmaceuticals, a multinational company headquartered in Naples, Florida, and London, UK, announced its acquisition of Enso Discoveries, LLC, a Manhattan, Kansas-based biotech company specializing in regenerative medicine. The acquisition was revealed at the 10th annual Animal Health, Nutrition, and Technology Innovation Europe. - April 30, 2025 - Vetirus Animal Health
Mirror Biologics Announces Publication of Clinical Results Showing Potential for Allo-Priming to Provide Broad Protection to Elderly from Respiratory Viral Infection
A new approach for pandemic preparedness and protection of the elderly from any type of respiratory viral infection. Five injections over two weeks provides possible universal viral protection without need for booster shots. - April 28, 2025 - Mirror Biologics, Inc.
Caris Life Sciences Collaborates with Meaningful Insights Biotech Analytics (MiBA) to Advance Oncology Education and Quality of Care
Caris Life Sciences® (Caris), a leading next-generation AI TechBio company and precision medicine pioneer, today announced a strategic collaboration with MiBA, an innovative healthcare technology company to provide physician education and insights to accelerate research, identify and... - April 24, 2025 - MiBA
Parvus Announces Achievement of First Milestone from its Collaboration Agreement with AbbVie to Develop IBD Therapies Based on the Parvus Nanomedicine Platform Technology
IND-enabling nonclinical and manufacturing activities executed by Parvus met prospective criteria resulting in the first milestone payment from AbbVie. - April 21, 2025 - Parvus Therapeutics U.S., Inc.
Minus K Congratulates to the following winners of their 2024/2025 Educational Giveaway
Celebrating its’ tenth year of their U.S. Educational Giveaway, Minus K Technology has to-date granted over $100,000 of its superior performing patented Negative-Stiffness low-frequency passive mechanical vibration isolators to colleges and universities in the USA. - April 03, 2025 - Minus K Technology Inc.
Apeximmune Therapeutics Announces Successful Close of Series A Fundraising Round to Advance Next-Generation Immunotherapies
Apeximmune Therapeutics, a biotechnology company pioneering next-generation immunotherapies, today announced the successful close of its Series A financing round, raising $21.3 million, exceeding its original goal of $20 million. The funding was led by PharmaEssentia Corporation, with participation... - April 01, 2025 - Apeximmune Therapeutics
Huntington Study Group Announces Executive Director of Clinical Operations
The Huntington Study Group® and HSG Clinical Research, Inc. (together, “HSG”) are pleased to introduce Carolyn Schultz-Walter as the Executive Director of Clinical Operations. With over 25 years of global clinical operations experience spanning both sponsor and clinical research... - March 31, 2025 - Huntington Study Group
Dr. Mike Chan: Leading the Future of Organ-Specific Stem Cell Therapies with Revolutionary Treatments in Regenerative Medicine
Dr. Mike Chan is a global leader in regenerative medicine, transforming lives with stem cells, exosomes, and peptides. His innovative treatments regenerate tissues, restore healing, and enhance vitality. Patients experience renewed hope, improved energy, and recovery from chronic conditions. His groundbreaking work is reshaping the future of healthcare. - March 28, 2025 - Dr. Mike Chan
Thar Process and Clean Heat Technologies Integrate CO2 Heat Pump Technology to Make Supercritical CO2 Technology a Low Cost Solution
Thar Process and Clean Heat Technologies have successfully engineered, integrated and installed electric heat pumps using CO2 - R744 - as the upcycled, natural refrigerant. The technology partnership means that Thar Process' clients can benefit from lower operating costs. Thar is known for it's innovative use of CO2 for extracting flavors, fragrances, medicinal and therapeutic compounds both in it's GMP certified facility in Pittsburgh and at client sites globally. - March 24, 2025 - Thar Process
SignaBlok to Present Preclinical Data on TREM-1-Targeting Drug for the Treatment of Cancer at the American Association for Cancer Research (AACR) Annual Meeting 2025
SignaBlok will present positive preclinical data on targeting innate inflammation for the treatment of hard-to-treat cancers. In combination with standard-of-care chemotherapy, SignaBlok's new mechanism-based inhibitor of TREM-1, an inflammation amplifier, prevents cancer recurrence, improves complete response rate and survival in experimental pancreatic cancer. In combination with anti-PD-L1 treatment, it overcomes pancreatic cancer resistance to immunotherapy. - March 21, 2025 - SignaBlok, Inc.
SignaBlok to Present Preclinical Data on TREM-1-Targeting Drug at the Respiratory Innovation Summit and American Thoracic Society International Conference 2025
SignaBlok will present positive preclinical data on targeting innate inflammation for the treatment of sepsis and pulmonary diseases. In experimental sepsis, SignaBlok's new mechanism-based inhibitor of TREM-1, an inflammation amplifier, protects from death with the level of protection not declining at delayed treatment times. In pulmonary inflammation and fibrosis in rats and mice, it reduces neutrophil infiltration in the lungs and reverses fibrosis. - March 21, 2025 - SignaBlok, Inc.